Keyword : immunotherapy
ASCO 2026: key trials
Cardiovascular complications of modern therapy in oncohematology: the role of the cardiologist in multidisciplinary patient managementAuthor:Nemish I.L. Дата: 2026-10-26
Therapeutic approach to laryngeal and pharyngeal tumors: from traditional methods to immunotherapyAuthors: Lukach E.V. Volobuev M.A. Serezhko Yu.O. Дата: 2026-10-07
Functional status of the thyroid gland as a factor modifying the level of PD-L1 expression by tumor cells and immunocompetent T cells of the paratumoral microenvironmentAuthors: Kolomiiets А.А. Lyalkin S.A. Т. 16, №2 (62)
Paradigm reset: modern approaches to lung cancer diagnosis and treatmentAuthor:Zviahina O.V. Т. 15, №3 (59)
Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trialТ. 14, №4 (56)
KEYNOTE-006 study: results of 10-year follow-up of pembrolizumab versus ipilimumab in advanced melanomaТ. 14, №4 (56)
From theory to practice. The art of lung cancer treatment
Management of immunotherapy toxicity: European Society for Medical Oncology (ESMO) clinical guidelines for diagnosis, treatment and patient follow-up
New therapeutic options in the treatment of patients with relapsed/refractory B-cell acute lymphoblastic leukemiaТ. 14, №1 (53)
Immunological markers of dendritic cell vaccine response in glioblastoma patientsAuthors: Skachkova O.V. Glavatskyi O.Ya. Zemskova O.V. Gorbach O.I.... Т. 14, №1 (53)
Expanding the role of immuno-oncology treatment in the management of patients with melanoma or triple-negative breast cancerТ. 13, №4 (52)
Modern approaches to the diagnosis and treatment of lymphoproliferative diseases
Prospects for the use of pembrolizumab in the treatment of previously untreated patients with advanced malignant pleural mesotheliomaAuthor:Nemish I.L. Т. 13, № 3 (51)
